All Articles

Browse the full archive, newest first.

Capping Insulin Costs at $35 May Improve Treatment Adherence for Type 2 Diabetes

A recent study suggests that limiting insulin prices to $35 per month could enhance adherence to treatment among individuals with type 2 diabetes, highlighting the potential impact of cost on health outcomes.

Editorial Staff Apr 7

Life

Gilead Acquires Tubulis for Over $3 Billion to Boost Oncology Portfolio

In a significant move to enhance its oncology pipeline, Gilead has announced the acquisition of Tubulis, a German biotech firm, for more than $3 billion.

Editorial Staff Apr 7

Money

OceanFirst-Flushing merger deal gains shareholder nod

Strategic angle: Shareholders approve the merger between OceanFirst and Flushing.

Editorial Staff Apr 7

Money

Apple's iPhone sales continue to surge as iPhone 17 outpaces iPhone 16

Strategic angle: Apple's latest iPhone model is experiencing impressive sales growth, surpassing its predecessor.

Editorial Staff Apr 7

Politics

Trump warns Iran it could be destroyed 'in one night' as deadline nears

Donald Trump escalates threats against Iran as the US deadline approaches.

Editorial Staff Apr 7

Tech

Broadcom agrees to expanded chip deals with Google, Anthropic - CNBC

Broadcom agrees to expanded chip deals with Google, Anthropic CNBC

Editorial Staff Apr 7

Money

Rare Earth & Graphite Assets in Brazil Offer Major Upside Potential

Strategic angle: Streetwise Reports highlights the investment opportunities in Brazil's rare earth and graphite sectors.

Editorial Staff Apr 7

Money

ASML shares fall after proposed U.S. export curbs target an already fragile China market

Strategic angle: Proposed U.S. restrictions would target ASML's deep ultraviolet (DUV) lithography machine, which Chinese companies have so far been able to access.

Editorial Staff Apr 7

Money

Free Women's Carpe Diem Shorts Available Now

Strategic angle: Discover the comfort and style of our Light Cobalt Blue Casual Shorts.

Editorial Staff Apr 7

Life

Merck's HIV Prevention Pill: A Cost-Effective Solution Awaiting Generic Production

With estimates suggesting Merck's experimental HIV prevention pill could cost under $5 annually, researchers are calling for the company to allow generic production.

Editorial Staff Apr 7